Pfizer rescues biotech
The $43bn deal for Seagen marks the biggest biopharma acquisition since the pre-crash takeouts of Allergan and Celgene.
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
The world needs Garp, according to Abbvie
After years of slow progress, and with very little supporting clinical data, Abbvie pledges to push into a major Garp inhibition programme.
The end of the Humira era
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
Biopharma's stock market winners of 2022 revealed
Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.
The biggest-selling drugs of 2023
Move over Comirnaty: Keytruda takes top spot as its indications broaden and demand for Covid vaccines recedes.
